OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
A report into the Swiss biotech sector has shown that there is continued growth in the sector, which has received investments from public and private companies worth CHF 1.2 billion (US$1.2 billion).
A report into the Swiss biotech sector, launched on April 21, 2020 by the Swiss Biotech Association, has shown that there is continued growth in the sector, which has received investments from public and private companies worth CHF 1.2 billion (US$1.2 billion).
Other key findings of the report include a boost in revenues for the sector, which reached CHF 4.8 billion (US$4.9 billion) in 2019, and the emergence of new strengths, with major companies expanding production capacity. Additionally, the report highlighted the favorable and comprehensive life sciences ecosystem that exists in Switzerland, which has contributed to making it an attractive funding environment.
“The Swiss Biotech Report 2020 shows that Switzerland has a comprehensive life sciences ecosystem-from research to manufacturing-that Swiss biotech companies can rely on and thus continue to thrive,” said Michael Altorfer, CEO Swiss Biotech Association, in an April 21, 2020 press release. “Economically, life sciences are a major pillar of the Swiss economy, accounting for 40% of exports with a truly global reach. The report also shows that the sector is not standing still with growth in new areas and a rise in international collaborations and investments. However, I would caution that more work is needed to attract large institutional investors who shy away from this sector despite its proven and attractive track record to deliver above average return on investment.”
Source: Swiss Biotech Association